% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • biotechbeagle biotechbeagle Sep 10, 2013 10:08 PM Flag

    Imgn 901 analyst comments

    Jefferies analyst Thomas Wei reiterated a Buy rating and $21 price target on Immunogen Inc. (NASDAQ: IMGN) Monday, noting positive feedback on IMGN-901 from a consultant call.

    "On a Jefferies hosted lung cancer specialist call, our physician consultant expressed a favorable view of IMGN’s lorvotuzumab mertansine (IMGN901), an antibody drug conjugate being evaluated in combination with chemotherapy for the treatment of small cell lung cancer (SCC) in the ongoing Phase 2 NORTH trial," Wei notes. "We were incrementally encouraged by the feedback but await NORTH data in mid-2014. IMGN901 currently represents upside to our valuation for IMGN."

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks, noticed this recently on the IV board. IF 901 is commercially viable this would be big for IMGN. For some reason I still don't expect positive results from 901. If IMGN management thinks 901 will be a break through, why would insiders sell any of their stock? Skeptical, but always hopeful.

7.28+0.19(+2.68%)Feb 12 4:00 PMEST